ABL is pleased to announce the immediate available of two new DeepChek® Assays intended to be used for:
- Determining eligibility for CCR5 antagonist treatment in patients infected with human immunodeficiency virus 1 (HIV-1) – DeepChek®-HIV V3 Loop/Tropism Assay
- HBV genotyping, drug resistance and vaccine escape assessment – DeepChek®-HBV RT Genotyping and DR Assay